OBJECTIVE: To examine the long-term functional and oncologic results in patients who underwent transoral robotic surgery (TORS) as primary therapy or as part of combined therapy for oropharyngeal squamous cell carcinoma arising in the tonsil or base of tongue. PATIENTS AND METHODS: We reviewed a prospective TORS database of patients with squamous cell carcinoma arising in the tonsil or base of tongue treated between March 2007 and February 2009 to determine oncologic outcomes at 24 months or more of follow-up. The presenting tumor stage, histopathologic factors, surgical margins, and adjuvant treatment extent were evaluated. Functional outcomes included gastrostomy tube dependence and tracheostomy dependence. Oncologic outcomes included local, regional, and distant control and disease-specific and recurrence-free survival. RESULTS: A total of 66 TORS patients were followed up for a minimum of 2 years. Most (97.0%; 64 of 66) were able to eat orally within 3 weeks after surgery before starting adjuvant therapy. Long-term gastrostomy tube use was required in 3 of the 66 (4.5%) and long-term tracheotomy in 1 (1.5%). Three-year estimated local control and regional control were 97.0% and 94.0%, respectively. Two-year disease-specific survival and recurrence-free survival were 95.1% and 92.4%, respectively. CONCLUSION: With appropriate adjuvant therapy, TORS achieves excellent functional results for patients with oropharyngeal squamous cell carcinoma. Oncologic outcomes are equivalent or superior to results of other surgical and nonsurgical treatments.
OBJECTIVE: To examine the long-term functional and oncologic results in patients who underwent transoral robotic surgery (TORS) as primary therapy or as part of combined therapy for oropharyngeal squamous cell carcinoma arising in the tonsil or base of tongue. PATIENTS AND METHODS: We reviewed a prospective TORS database of patients with squamous cell carcinoma arising in the tonsil or base of tongue treated between March 2007 and February 2009 to determine oncologic outcomes at 24 months or more of follow-up. The presenting tumor stage, histopathologic factors, surgical margins, and adjuvant treatment extent were evaluated. Functional outcomes included gastrostomy tube dependence and tracheostomy dependence. Oncologic outcomes included local, regional, and distant control and disease-specific and recurrence-free survival. RESULTS: A total of 66 TORSpatients were followed up for a minimum of 2 years. Most (97.0%; 64 of 66) were able to eat orally within 3 weeks after surgery before starting adjuvant therapy. Long-term gastrostomy tube use was required in 3 of the 66 (4.5%) and long-term tracheotomy in 1 (1.5%). Three-year estimated local control and regional control were 97.0% and 94.0%, respectively. Two-year disease-specific survival and recurrence-free survival were 95.1% and 92.4%, respectively. CONCLUSION: With appropriate adjuvant therapy, TORS achieves excellent functional results for patients with oropharyngeal squamous cell carcinoma. Oncologic outcomes are equivalent or superior to results of other surgical and nonsurgical treatments.
Authors: G Calais; M Alfonsi; E Bardet; C Sire; T Germain; P Bergerot; B Rhein; J Tortochaux; P Oudinot; P Bertrand Journal: J Natl Cancer Inst Date: 1999-12-15 Impact factor: 13.506
Authors: Samuel G Shiley; Christopher A Hargunani; Judith M Skoner; John M Holland; Mark K Wax Journal: Otolaryngol Head Neck Surg Date: 2006-03 Impact factor: 3.497
Authors: M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: Sarah E Mowry; Allen Ho; Maria M Lotempio; Ahmad Sadeghi; Keith E Blackwell; Marilene B Wang Journal: Laryngoscope Date: 2006-09 Impact factor: 3.325
Authors: Mitchell Machtay; David I Rosenthal; Diane Hershock; Heather Jones; Shirnett Williamson; Michael J Greenberg; Gregory S Weinstein; Victor M Aviles; Ara A Chalian; Randal S Weber Journal: J Clin Oncol Date: 2002-10-01 Impact factor: 44.544
Authors: James T Parsons; William M Mendenhall; Scott P Stringer; Robert J Amdur; Russell W Hinerman; Douglas B Villaret; Giselle J Moore-Higgs; Bruce D Greene; Tod W Speer; Nicholas J Cassisi; Rodney R Million Journal: Cancer Date: 2002-06-01 Impact factor: 6.860
Authors: William R Kennedy; Michael P Herman; Rohan L Deraniyagala; Robert J Amdur; John W Werning; Peter Dziegielewski; Jessica Kirwan; Christopher G Morris; William M Mendenhall Journal: Eur Arch Otorhinolaryngol Date: 2016-04-08 Impact factor: 2.503
Authors: Robert L Foote; Yolanda I Garces; Michelle A Neben Wittich; Daniel J Ma; Sean S Park; Julian R Molina; Scott H Okuno; Katharine A Price; Steven E Schild; Samir H Patel Journal: Mayo Clin Proc Date: 2012-11 Impact factor: 7.616
Authors: P Sinha; W T Thorstad; B Nussenbaum; B H Haughey; D R Adkins; D Kallogjeri; J S Lewis Journal: Oral Oncol Date: 2013-11-06 Impact factor: 5.337
Authors: Neil D Gross; F Christopher Holsinger; J Scott Magnuson; Umamaheswar Duvvuri; Eric M Genden; Tamer Ah Ghanem; Kathleen L Yaremchuk; David Goldenberg; Matthew C Miller; Eric J Moore; Luc Gt Morris; James Netterville; Gregory S Weinstein; Jeremy Richmon Journal: Head Neck Date: 2016-03-07 Impact factor: 3.147
Authors: Arun Sharma; Sapna Patel; Fred M Baik; Grant Mathison; Brendan H G Pierce; Samir S Khariwala; Bevan Yueh; Stephen M Schwartz; Eduardo Méndez Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-07-01 Impact factor: 6.223